• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

    81.80 +2.61 (+3.30%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,301,790
    Open 79.53
    Bid (Size) 79.56 (100)
    Ask (Size) 84.00 (100)
    Prev. Close 79.19
    Today's Range 79.11 - 81.99
    52wk Range 39.72 - 86.74
    Shares Outstanding 141,797,854
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +2.7%
    +2.7%
    1 Month
    +8.5%
    +8.5%
    3 Month
    +8.9%
    +8.9%
    6 Month
    +3.4%
    +3.4%
    1 Year
    +104.8%
    +104.8%

    More News

    Read More
    News headline image
    QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
    Via InvestorPlace
    Ionis Pharmaceuticals (NASDAQ:IONS) Shares Surge After Crushing Q1 Estimates and Raising Full-Year Guidance ↗
    Via Chartmill
    News headline image
    Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗
    Via MarketBeat
    News headline image
    Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference ↗
    Via MarketBeat
    News headline image
    Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to host 2026 virtual Annual Meeting of Stockholders
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present at upcoming investor conferences
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis (IONS) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Ionis reports first quarter 2026 financial results and highlights progress on key programs
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis (IONS) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to hold first quarter 2026 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
    Via MarketMinute
    News headline image
    When Insider Selling Is a Good Thing: 2 Stocks to Watch ↗
    Via MarketBeat
    News headline image
    Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
    Via The Motley Fool
    News headline image
    Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
    Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
    What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
    The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 81.80
    When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 07/02/26 04:00 PM ET
    What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 11.60B
    How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
    Ionis Pharmaceuticals, Inc. - Common Stock has 12B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.